Dr. Ferrajoli on Treatment of Elderly Patients With CLL

Alessandra Ferrajoli, MD
Published: Thursday, Oct 22, 2015



Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for elderly patients with chronic lymphocytic leukemia (CLL).

For elderly patients, as well as those without 17p deletion, a treatment option is the combination of chemoimmunotherapy with either fludarabine/cyclophosphamide/rituximab or bendamustine plus rituxumab. These combinations are most appropriate in patients who are more physically active, Ferrajoli adds. They also demonstrate overall remission rates of approximately 90% in these patients.

For patients with comorbidities, the combination of CD20 monoclonal antibodies with alkylating agents have been established as a beneficial treatment option. The combinations of obinutuzumab plus chlorambucil and ofatumumab plus chlorambucil have demonstrated response rates of 60% to 70%, and can achieve complete remissions. Both combinations are well-tolerated with no known impact on quality of life, Ferrajoli says.

SELECTED
LANGUAGE


Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for elderly patients with chronic lymphocytic leukemia (CLL).

For elderly patients, as well as those without 17p deletion, a treatment option is the combination of chemoimmunotherapy with either fludarabine/cyclophosphamide/rituximab or bendamustine plus rituxumab. These combinations are most appropriate in patients who are more physically active, Ferrajoli adds. They also demonstrate overall remission rates of approximately 90% in these patients.

For patients with comorbidities, the combination of CD20 monoclonal antibodies with alkylating agents have been established as a beneficial treatment option. The combinations of obinutuzumab plus chlorambucil and ofatumumab plus chlorambucil have demonstrated response rates of 60% to 70%, and can achieve complete remissions. Both combinations are well-tolerated with no known impact on quality of life, Ferrajoli says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x